MAM
EWTX icon

Martingale Asset Management’s Edgewise Therapeutics EWTX Stock Holding History

Martingale Asset Management’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-61,384
Closed -$672K – 824
2023
Q4 		$672K Sell
61,384
-10
-0% -$70 0.01% 538
2023
Q3 		$352K Sell
61,394
-10
-0% -$68 0.01% 661
2023
Q2 		$476K Buy
61,404
+4,641
+8% +$39.1K 0.01% 627
2023
Q1 		$379K Buy
56,763
+27,900
+97% +$259K 0.01% 672
2022
Q4 		$258K Buy
28,863
+3,648
+14% +$34.2K 0.01% 743
2022
Q3 		$249K Buy
+25,215
New +$255K 0.01% 743

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Martingale Asset Management's EWTX Position: Q1 2024 in Review

Martingale Asset Management sold out of Edgewise Therapeutics (EWTX) in Q1 2024, closing a stake of 61,384 shares — an estimated $672K sold.

Martingale Asset Management first reported a position in EWTX in Q3 2022 and held it in 6 quarters. The position peaked at $672K in Q4 2023. 129 funds tracked by Wall St. Rank hold EWTX as of Q1 2024.

  • Martingale Asset Management reported no remaining Edgewise Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Martingale Asset Management sold 61,384 Edgewise Therapeutics shares in Q1 2024, an estimated $672K.
  • Martingale Asset Management first reported a position in Edgewise Therapeutics in Q3 2022 and held it in 6 quarters.
  • Martingale Asset Management's Edgewise Therapeutics position peaked at $672K in Q4 2023.
  • 129 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2024.

Based on Martingale Asset Management's 13F filing for Q1 2024, filed 14 May 2024.